EYLEA

Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea Ltd (NASDAQ: OPT) is wet age-related macular degeneration, commonly referred to as AMD, and other...

This week could see up to nine companies price their IPOs. Here is a look at the companies looking to go public this week. Codiak Biosciences: Clinical stage biopharmaceutical Codiak Biosciences (NASDAQ: CDAK) plans to sell 5.5 million shares at a price point of $14 to $16. The...

One's pain is another's gain, and this phrase ringed in true in the case of Regeneron Pharmaceuticals Inc (NASDAQ: REGN). Jefferies deemed fit to upgrade shares on improved prospects for its eye disorder drug Eylea following disclosure of adverse events associated with Novartis AG's (...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were trading higher Tuesday after Eylea, its product to treat retinal conditions, snagged another approval. What Happened Regeneron said Tuesday ahead of the market open that the FDA approved the Chemistry, Manufacturing and Controls Prior...

Shares of Clearside Biomedical Inc (NASDAQ: CLSD), a biopharmaceutical company that focuses on the treatment of serious eye diseases, plunged 60 percent Monday after announcing disappointing results from a Phase 3 study. What Happened Clearside said in a press release its Phase 3 clinical...

Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is up about 5 percent. As the earnings season kicks into high gear and amid several other catalysts, August is likely to be an action-packed...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares fell 31 percent over the last six months, and the company's headwinds appear unending. The biotech firm lost an advocate Wednesday on the basis of a rough outlook for Eylea and Dupixent treatments. The Rating Canaccord Genuity analyst John...

BMO Capital Markets said in a note CHS-3351 may be Coherus Biosciences Inc (NASDAQ: CHRS)'s most underappreciated asset. CHS-3351 is a biosimilar of ranibizumab, an mAb fragment against VEGF-A used to treat neovascular age-related macular degeneration, or AMD. Promising Potential Analyst Ian...

Initiating coverage of Alimera Sciences Inc (NASDAQ: ALIM) at a Buy rating and a $4 price target, Rodman & Renshaw said it views the company's commercialized product lluvien, which is a fluocinolone acetonide intravitreal implant, is differentiated from other corticosteroid treatment options...

After the release of Ophthotech Corp (NASDAQ: OPHT)'s fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration. The Disappointment The company announced disappointing...

Following a stay granted to allow Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s PCSK9 franchise Praluent to stay in the market, Credit Suisse said the development is a mild positive for the company. The firm said the company's shares would trade up 2–4 percent based on the headline news,...

After a strong third quarter with a 7-percent revenue increase, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) justifies a Buy rating from Argus analysts with a $450 target. Analysts also increased Regeneron's 2016 EPS estimate from $11 to $11.58 after the company's GAAP EPS rose 25 percent. Although...

Opthotech Corp (NASDAQ: OPHT) shares plummeted 84.6 percent on Monday morning after the company reported negative results in its Phase III OPH1002 and OPH1003 studies. The two combination trials in wet age-related macular degeneration (AMD) failed to meet primary endpoints. “We found no...

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) is a San Diego-based small-cap pharmaceutical company that specializes in the ophthalmology space. The company is coming off an impressive 81 percent year-over-year increase in revenues in its most recent quarter and clocked nearly a 20 percent...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the Phase 2 CAPELLA trial of Eylea co-formulated with an anti-PDGFR-beta antibody, runicumab, did not meet the primary endpoint. Baird’s Brian P. Skorney maintained a Neutral rating on the company, with a price target of $448. He...